Dr. Dylan Kahl is a patent agent at Wilson Sonsini Goodrich & Rosati. He is a member of the firm's patents and innovations practice, where he assists with various matters related to the diligence for and the preparation and prosecution of patent applications in the fields of chemistry, medicinal chemistry, pharmaceuticals, biochemistry, and biotechnology.
During graduate school, Dylan studied under Dr. Scott D. Larsen at the Valtech Medicinal Chemistry Core, where he worked on a variety of projects related to small-molecule drug discovery and design, including the design and synthesis of potent small-molecule anti-fibrotic agents as lead compounds and the production of many successful affinity pull-down probes for target identification studies. Given his background, Dylan has a strong understanding of technological innovations spanning both the fields of chemistry and biology.
Dr. Dylan Kahl is a patent agent at Wilson Sonsini Goodrich & Rosati. He is a member of the firm's patents and innovations practice, where he assists with various matters related to the diligence for and the preparation and prosecution of patent applications in the fields of chemistry, medicinal chemistry, pharmaceuticals, biochemistry, and biotechnology.
During graduate school, Dylan studied under Dr. Scott D. Larsen at the Valtech Medicinal Chemistry Core, where he worked on a variety of projects related to small-molecule drug discovery and design, including the design and synthesis of potent small-molecule anti-fibrotic agents as lead compounds and the production of many successful affinity pull-down probes for target identification studies. Given his background, Dylan has a strong understanding of technological innovations spanning both the fields of chemistry and biology.
- Ph.D., Medicinal Chemistry, University of Michigan, 2018
- B.S., Biochemistry, Arizona State University, 2014Cum Laude; Dean's List, 2012-2014; Recipient, New American University Scholar—Dean's Award, 2010-2014
- U.S. Patent and Trademark Office
- Ph.D., Medicinal Chemistry, University of Michigan, 2018
- B.S., Biochemistry, Arizona State University, 2014Cum Laude; Dean's List, 2012-2014; Recipient, New American University Scholar—Dean's Award, 2010-2014
- U.S. Patent and Trademark Office
Select Publications
- Co-author, "5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Reponse Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma," 62(9) Journal of Medicinal Chemistry4350-69, May 9, 2019
- Co-author with E.M. Lisabeth et al., "Identification of Pirin as a Molecular Target of the CCG-1423/CCG-203971 Series of Antifibrotic and Antimetastatic Compounds," 2(2) ACS Pharmacology & Translational Science 92-100, 2019
Select Publications
- Co-author, "5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Reponse Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma," 62(9) Journal of Medicinal Chemistry4350-69, May 9, 2019
- Co-author with E.M. Lisabeth et al., "Identification of Pirin as a Molecular Target of the CCG-1423/CCG-203971 Series of Antifibrotic and Antimetastatic Compounds," 2(2) ACS Pharmacology & Translational Science 92-100, 2019
Under the terms of the agreement, Dunad will apply its tunable and highly selective platform to generate novel covalent and targeted protein degrading small molecule drugs focusing on up to four drug targets agreed with Novartis. Dunad will also be responsible for program execution up to lead optimization. Novartis will contribute target and ligand knowledge, as well as access to unique assays and models, and will fully fund the research collaboration. Novartis has an exclusive option to develop and commercialize products resulting from the research programs directed against up to four drug targets. Upon exercise of this option, Novartis will assume responsibility for future development, manufacturing, and global commercialization of the small molecule therapeutic products generated against the agreed targets.
Dunad will receive $24 million in an upfront payment and equity investment, as well as significant research funding. Dunad will also be eligible to receive up to $1.3 billion in discovery, regulatory, and sales-based milestones, in addition to royalty payments.
The Wilson Sonsini team that advised Dunad on the collaboration included Lou Lieto, Gregory Mitchell, Wei Li, and Dylan Kahl.
For more information, please see Dunad’s press release.
- Privacy Policy
- Terms of Use
- Accessibility